Last updated on June 2020

HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Brief description of study

This is an open-label, single arm study design to evaluate HEPLISAV-B in adults with ESRD who are initiating or undergoing hemodialysis.

Detailed Study Description

Eligible participants will receive single doses of HEPLISAV-B at Weeks 0, 4, 8, and 16 and will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the immunogenicity over a 20-week period and safety over a 68-week period.

Clinical Study Identifier: NCT03934736

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.